Table 2.
Clinical remission in JIA patients treated with DMARD according to treatment group. Retrospective study results
| SDMARD alone n = 106 (53%) |
SDMARD combined n = 37 (19%) |
SDMARD BDMARD combined n = 48 (24%) |
BDMARD alone n = 8 (4%) |
Clinical remission n = 199 |
p | |
|---|---|---|---|---|---|---|
| JIA ILAR category a n (%) | ||||||
| Oligoarticular | 66 (62) | 18 (49) | 25 (52) | 3 (1) | 112 (56) | 0.003 |
| Persistent | 61 (92) | 13 (72) | 17 (68) | 1 (33) | 92 (82) | |
| HLA B27 absence a n (%) | 89 (84) | 33 (89) | 25 (52) | 6 (75) | 153 (85) | 0,023 |
| Synthetic DMARD a n (%) | ||||||
| Metotrexate | 78 (74) | 18 (49) | 15 (31) | 0 | 108 (54) | < 0.001 |
| No AE with DMARD a n (%) | 81 (76) | 24 (65) | 33 (69) | 1 (13) | 139 (70) | 0.005 |
| Dose taperingn = 132 | ||||||
| Dose tapering a n (%) | 80 (75) | 18 (49) | 29 (60) | 5 (62) | 132 (66) | 0,018 |
| Tapering method n (%) | 0,071 | |||||
| Interval increase | 35 (44) | 8 (44) | 12 (41) | 5 (100) | 60 (45) | |
| Dose decrease | 30 (37) | 7 (39) | 15 (31) | 0 | 46 (35) | |
| Both | 15 (19) | 3 (17) | 1 (3) | 0 | 19 (14) | |
| Tapering duration, months, median (IQR) | 15 (20) | 14 (27) | 21 (25) | 40 (30) | 16 (28) | 0,190 |
| Relapse amid tapering, n (%) | 10 (13) | 5 (28) | 4 (14) | 0 | 19 (14) | 0,330 |
| Withdrawal after tapering a, n (%) | 69 (86) | 16 (89) | 10 (34) | 1 (13) | 95 (72) | < 0,001 |
| Withdrawal due to CRn = 124 | ||||||
| Withdrawal due to CR | 71 (67) | 29 (78) | 21 (44) | 3 (38) | 124 (62) | 0,728 |
| Treatment duration to withdrawal due to RC a, months, median (IQR) | 31 (26) | 42 (43) | 34 (54) | 68 (71) | 31 (30) | 0,037 |
| Relapse after withdrawal n (%) | 50 (70) | 16 (55) | 11 (52) | 2 (67) | 79 (64) | 0,783 |
| Time to relapse, months, median (IQR) | 13 (25) | 42 (41) | 10 (18) | 14 | 14 (32) | 0,122 |
SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number, HLA B27 Human leukocyte antigen, AE Adverse event, IQR Interquartile range, CR Clinical remission
ap < 0,05 Statistically significant differences using the χ2 or Mann Whitney U tests